Evaluation of a 3-amino-8-azabicyclo[3.2.1]octane replacement in the CCR5 antagonist maraviroc

Rémy C Lemoine; Ann C Petersen; Lina Setti; Thomas Baldinger; Jutta Wanner; Andreas Jekle; Gabrielle Heilek; André deRosier; Changhua Ji; David M Rotstein

doi:10.1016/j.bmcl.2010.01.080

Evaluation of a 3-amino-8-azabicyclo[3.2.1]octane replacement in the CCR5 antagonist maraviroc

Bioorg Med Chem Lett. 2010 Mar 1;20(5):1674-6. doi: 10.1016/j.bmcl.2010.01.080. Epub 2010 Jan 21.

Authors

Rémy C Lemoine¹, Ann C Petersen, Lina Setti, Thomas Baldinger, Jutta Wanner, Andreas Jekle, Gabrielle Heilek, André deRosier, Changhua Ji, David M Rotstein

Affiliation

¹ Department of Medicinal Chemistry, Roche Palo Alto, 3431 Hillview Avenue, Palo Alto, CA 94304, USA. remy.lemoine@roche.com

PMID: 20137937
DOI: 10.1016/j.bmcl.2010.01.080

Abstract

The bicyclic 5-amino-3-azabicyclo[3.3.0]octanes were shown to be effective replacements for the 3-amino-8-azabicyclo[3.2.1]octane found in the CCR5 antagonist maraviroc.

MeSH terms

Anti-HIV Agents / chemical synthesis
Anti-HIV Agents / chemistry*
Anti-HIV Agents / pharmacology
Azabicyclo Compounds / chemistry*
CCR5 Receptor Antagonists*
Cell Line, Tumor
Cyclohexanes / chemical synthesis
Cyclohexanes / chemistry*
Cyclohexanes / pharmacology
HIV Fusion Inhibitors / chemical synthesis
HIV Fusion Inhibitors / chemistry*
HIV Fusion Inhibitors / pharmacology
Humans
Maraviroc
Models, Chemical
Receptors, CCR5 / metabolism
Triazoles / chemical synthesis
Triazoles / chemistry*
Triazoles / pharmacology

Substances

Anti-HIV Agents
Azabicyclo Compounds
CCR5 Receptor Antagonists
Cyclohexanes
HIV Fusion Inhibitors
Receptors, CCR5
Triazoles
Maraviroc